Display Settings:

Format

Send to:

Choose Destination

    Science. 1998 Jan 2;279(5347):98-102.

    Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.

    Rozwarski DA, Grant GA, Barton DH, Jacobs WR Jr, Sacchettini JC.

    Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX 77843, USA.

    The preferred antitubercular drug isoniazid specifically targets a long-chain enoyl-acyl carrier protein reductase (InhA), an enzyme essential for mycolic acid biosynthesis in Mycobacterium tuberculosis. Despite the widespread use of this drug for more than 40 years, its precise mode of action has remained obscure. Data from x-ray crystallography and mass spectrometry reveal that the mechanism of isoniazid action against InhA is covalent attachment of the activated form of the drug to the nicotinamide ring of nicotinamide adenine dinucleotide bound within the active site of InhA.

    PMID: 9417034 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read

    Structures reported by this article

    Patient drug information